Hollsteen
← Everpure

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 FY2016: $32.0M · 10-Q 0001564590-16-020289 filed Jun 3, 2016Research and development · Q2 FY2016: $38.0M · 10-Q 0001628280-16-019406 filed Sep 6, 2016Research and development · Q3 FY2016: $43.0M · 10-Q 0001564590-15-011439 filed Dec 11, 2015Research and development · Q4 FY2016: $54.0M · derived · 10-K 0001628280-17-003034 filed Mar 29, 2017Research and development · Q1 FY2017: $53.0M · 10-Q 0001628280-17-006263 filed Jun 7, 2017Research and development · Q2 FY2017: $59.0M · 10-Q 0001628280-16-019406 filed Sep 6, 2016Research and development · Q3 FY2017: $62.0M · 10-Q 0001628280-16-022007 filed Dec 13, 2016Research and development · Q4 FY2017: $73.0M · derived · 10-K 0001628280-18-003579 filed Mar 26, 2018Research and development · Q1 FY2018: $65.0M · 10-Q 0001628280-17-006263 filed Jun 7, 2017Research and development · Q2 FY2018: $69.0M · 10-Q 0001628280-17-009061 filed Sep 5, 2017Research and development · Q3 FY2018: $69.0M · 10-Q 0001628280-17-012265 filed Dec 8, 2017Research and development · Q4 FY2018: $75.0M · derived · 10-K 0001628280-19-003437 filed Mar 26, 2019Research and development · Q1 FY2019: $78.0M · 10-Q 0001628280-18-007756 filed Jun 8, 2018Research and development · Q2 FY2019: $84.0M · 10-Q 0001628280-18-011594 filed Sep 4, 2018Research and development · Q3 FY2019: $91.0M · 10-Q 0001628280-18-014872 filed Dec 6, 2018Research and development · Q4 FY2019: $97.0M · derived · 10-K 0001628280-20-004133 filed Mar 27, 2020Research and development · Q1 FY2020: $105M · 10-Q 0001628280-19-007753 filed Jun 7, 2019Research and development · Q2 FY2020: $107M · 10-Q 0001628280-19-011331 filed Aug 30, 2019Research and development · Q3 FY2020: $107M · 10-Q 0001628280-19-014877 filed Dec 9, 2019Research and development · Q4 FY2020: $115M · derived · 10-K 0001628280-21-005538 filed Mar 25, 2021Research and development · Q1 FY2021: $112M · 10-Q 0001628280-20-009289 filed Jun 11, 2020Research and development · Q2 FY2021: $115M · 10-Q 0001628280-20-013458 filed Sep 11, 2020Research and development · Q3 FY2021: $123M · 10-Q 0001628280-20-017299 filed Dec 9, 2020Research and development · Q4 FY2021: $130M · derived · 10-K 0001628280-22-008643 filed Apr 7, 2022Research and development · Q1 FY2022: $131M · 10-Q 0001628280-21-011838 filed Jun 8, 2021Research and development · Q2 FY2022: $140M · 10-Q 0001628280-21-018247 filed Sep 8, 2021Research and development · Q3 FY2022: $148M · 10-Q 0001628280-21-024638 filed Dec 7, 2021Research and development · Q4 FY2022: $163M · derived · 10-K 0001628280-23-010275 filed Apr 3, 2023Research and development · Q1 FY2023: $161M · 10-Q 0001628280-22-017288 filed Jun 16, 2022Research and development · Q2 FY2023: $166M · 10-Q 0001628280-22-024939 filed Sep 15, 2022Research and development · Q3 FY2023: $180M · 10-Q 0001628280-22-031956 filed Dec 15, 2022Research and development · Q4 FY2023: $186M · derived · 10-K 0001628280-24-013860 filed Apr 1, 2024Research and development · Q1 FY2024: $185M · 10-Q 0001628280-23-022333 filed Jun 16, 2023Research and development · Q2 FY2024: $182M · 10-Q 0001628280-23-032228 filed Sep 14, 2023Research and development · Q3 FY2024: $182M · 10-Q 0001628280-23-041629 filed Dec 15, 2023Research and development · Q4 FY2024: $187M · derived · 10-K 0001628280-25-015044 filed Mar 27, 2025Research and development · Q1 FY2025: $194M · 10-Q 0001628280-24-027955 filed Jun 13, 2024Research and development · Q2 FY2025: $195M · 10-Q 0001628280-24-040066 filed Sep 11, 2024Research and development · Q3 FY2025: $200M · 10-Q 0001628280-24-050852 filed Dec 12, 2024Research and development · Q4 FY2025: $215M · derived · 10-K 0001474432-26-000027 filed Mar 25, 2026Research and development · Q1 FY2026: $222M · 10-Q 0001628280-25-030567 filed Jun 11, 2025Research and development · Q2 FY2026: $242M · 10-Q 0001474432-25-000046 filed Sep 10, 2025Research and development · Q3 FY2026: $256M · 10-Q 0001474432-25-000065 filed Dec 10, 2025Research and development · Q4 FY2026: $243M · derived · 10-K 0001474432-26-000027 filed Mar 25, 2026Research and development · Q1 FY2027: $259M · 10-Q 0001474432-26-000061 filed Jun 5, 2026Research and development · Q2 FY2027: $294M · 10-Q 0001474432-26-000088 filed Sep 4, 2026187a29432Q1 FY2016Q2 FY2027Q4 FY2024
$MResearch and development · Q4 FY2023: $186M · derived · 10-K 0001628280-24-013860 filed Apr 1, 2024Research and development · Q1 FY2024: $185M · 10-Q 0001628280-23-022333 filed Jun 16, 2023Research and development · Q2 FY2024: $182M · 10-Q 0001628280-23-032228 filed Sep 14, 2023Research and development · Q3 FY2024: $182M · 10-Q 0001628280-23-041629 filed Dec 15, 2023Research and development · Q4 FY2024: $187M · derived · 10-K 0001628280-25-015044 filed Mar 27, 2025Research and development · Q1 FY2025: $194M · 10-Q 0001628280-24-027955 filed Jun 13, 2024Research and development · Q2 FY2025: $195M · 10-Q 0001628280-24-040066 filed Sep 11, 2024Research and development · Q3 FY2025: $200M · 10-Q 0001628280-24-050852 filed Dec 12, 2024187a200186aQ4 FY2023Q3 FY2025Q4 FY2024
Q4 FY2024
187a$M
derived
All values (46)
PeriodValue ($M)Status
Q2 FY2027294reported
Q1 FY2027259reported
Q4 FY2026243derived
Q3 FY2026256reported
Q2 FY2026242reported
Q1 FY2026222reported
Q4 FY2025215derived
Q3 FY2025200reported
Q2 FY2025195reported
Q1 FY2025194reported
Q4 FY2024187derived
Q3 FY2024182reported
Q2 FY2024182reported
Q1 FY2024185reported
Q4 FY2023186derived
Q3 FY2023180reported
Q2 FY2023166reported
Q1 FY2023161reported
Q4 FY2022163derived
Q3 FY2022148reported
Q2 FY2022140reported
Q1 FY2022131reported
Q4 FY2021130derived
Q3 FY2021123reported
Q2 FY2021115reported
Q1 FY2021112reported
Q4 FY2020115derived
Q3 FY2020107reported
Q2 FY2020107reported
Q1 FY2020105reported
Q4 FY201997derived
Q3 FY201991reported
Q2 FY201984reported
Q1 FY201978reported
Q4 FY201875derived
Q3 FY201869reported
Q2 FY201869reported
Q1 FY201865reported
Q4 FY201773derived
Q3 FY201762reported
Q2 FY201759reported
Q1 FY201753reported
Q4 FY201654derived
Q3 FY201643reported
Q2 FY201638reported
Q1 FY201632reported

CSV with all sources · Technical ID: rnd

More metrics for Everpure

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Sources & calculation
Value
$187M (derived)
Period
Q4 FY2024, ended Feb 4, 2024 · quarterly value (3 months, not cumulative)
Calculation
Q4 = fiscal year − 9 months cumulative = 737M − 550M = $187M (FY value from 10-K 0001628280-25-015044; 9-month value from the Q3-10-Q)
Source
10-K, filed Mar 27, 2025 · 0001628280-25-015044
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$187MMar 27, 202510-K 0001628280-25-015044derived · confidence 1. · current